Breaking: Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) Buy Rating Kept by Deutsche Bank Today; The Target Price Given is $178

July 17, 2017 - By Maria Brooks

 Breaking: Jazz Pharmaceuticals plc   Ordinary Shares (NASDAQ:JAZZ) Buy Rating Kept by Deutsche Bank Today; The Target Price Given is $178

Investors sentiment decreased to 0.68 in 2016 Q4. Its down 0.13, from 0.81 in 2016Q3. It is negative, as 64 investors sold Jazz Pharmaceuticals plc – Ordinary Shares shares while 111 reduced holdings. 43 funds opened positions while 76 raised stakes. 50.81 million shares or 3.20% less from 52.49 million shares in 2016Q3 were reported.

Glenmede Communication Na has invested 0% in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). Green Square Lc has 0.18% invested in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). Panagora Asset Management stated it has 926 shares. Marshall Wace Limited Liability Partnership owns 68,487 shares or 0.05% of their US portfolio. Livforsakringsbolaget Skandia Omsesidigt has 29,125 shares. Calamos Advisors Lc accumulated 207,932 shares. British Columbia Investment Corp reported 25,749 shares or 0.02% of all its holdings. The Belgium-based Kbc Group Nv has invested 0.14% in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). Van Eck Assoc accumulated 25,773 shares. reported 7 shares or 0% of all its holdings. Glg Limited Liability holds 3,647 shares or 0.03% of its portfolio. Profund Advsrs Llc invested 0.01% in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). First Quadrant Limited Partnership Ca has invested 0.14% in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). Caisse De Depot Et Placement Du Quebec holds 9,500 shares. Wells Fargo & Comm Mn invested 0.02% of its portfolio in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ).

Since January 18, 2017, it had 0 insider purchases, and 9 selling transactions for $7.73 million activity. MILLER MICHAEL PATRICK had sold 200 shares worth $30,596. Treacy Paul also sold $116,666 worth of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) shares. 5,000 shares were sold by Winningham Rick E, worth $750,000 on Thursday, June 1. 2,500 shares valued at $400,000 were sold by Hooper Suzanne Sawochka on Tuesday, May 9. Another trade for 4,000 shares valued at $515,000 was made by Cox Russell J. on Wednesday, January 18. 11,458 shares valued at $1.74 million were sold by WILSON KAREN J on Monday, April 10.

Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) Rating Reaffirmed

Recently, In analysts note issued to investors and clients on Monday, 17 July, Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) shares have had their Buy Rating kept by equity analysts at Deutsche Bank, who currently has a $178 target price per share on firm. This target by Deutsche Bank gives the possibile upside of 14.92 % from the stock close price.

Investors sentiment decreased to 0.68 in 2016 Q4. Its down 0.13, from 0.81 in 2016Q3. It is negative, as 64 investors sold Jazz Pharmaceuticals plc – Ordinary Shares shares while 111 reduced holdings. 43 funds opened positions while 76 raised stakes. 50.81 million shares or 3.20% less from 52.49 million shares in 2016Q3 were reported.

Glenmede Communication Na has invested 0% in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). Green Square Lc has 0.18% invested in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). Panagora Asset Management stated it has 926 shares. Marshall Wace Limited Liability Partnership owns 68,487 shares or 0.05% of their US portfolio. Livforsakringsbolaget Skandia Omsesidigt has 29,125 shares. Calamos Advisors Lc accumulated 207,932 shares. British Columbia Investment Corp reported 25,749 shares or 0.02% of all its holdings. The Belgium-based Kbc Group Nv has invested 0.14% in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). Van Eck Assoc accumulated 25,773 shares. reported 7 shares or 0% of all its holdings. Glg Limited Liability holds 3,647 shares or 0.03% of its portfolio. Profund Advsrs Llc invested 0.01% in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). First Quadrant Limited Partnership Ca has invested 0.14% in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). Caisse De Depot Et Placement Du Quebec holds 9,500 shares. Wells Fargo & Comm Mn invested 0.02% of its portfolio in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ).

Since January 18, 2017, it had 0 insider purchases, and 9 selling transactions for $7.73 million activity. MILLER MICHAEL PATRICK had sold 200 shares worth $30,596. Treacy Paul also sold $116,666 worth of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) shares. 5,000 shares were sold by Winningham Rick E, worth $750,000 on Thursday, June 1. 2,500 shares valued at $400,000 were sold by Hooper Suzanne Sawochka on Tuesday, May 9. Another trade for 4,000 shares valued at $515,000 was made by Cox Russell J. on Wednesday, January 18. 11,458 shares valued at $1.74 million were sold by WILSON KAREN J on Monday, April 10.

Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) Ratings Coverage

Among 17 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 14 have Buy rating, 0 Sell and 3 Hold. Therefore 82% are positive. Jazz Pharmaceuticals has $229 highest and $124 lowest target. $184.53’s average target is 19.14% above currents $154.89 stock price. Jazz Pharmaceuticals had 31 analyst reports since August 3, 2015 according to SRatingsIntel. Stifel Nicolaus maintained it with “Buy” rating and $200 target in Wednesday, February 24 report. The company was maintained on Wednesday, June 7 by BMO Capital Markets. Mizuho initiated the shares of JAZZ in report on Friday, October 9 with “Buy” rating. As per Wednesday, February 24, the company rating was maintained by Mizuho. The stock of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) has “Buy” rating given on Monday, June 6 by Goldman Sachs. As per Thursday, April 6, the company rating was downgraded by Mizuho. The rating was maintained by Cantor Fitzgerald on Tuesday, June 27 with “Buy”. The firm has “Buy” rating given on Wednesday, May 11 by Mizuho. UBS maintained Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) rating on Wednesday, May 11. UBS has “Buy” rating and $168 target. On Friday, July 14 the stock rating was maintained by Piper Jaffray with “Buy”.

About 353,758 shares traded. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) has risen 1.25% since July 17, 2016 and is uptrending. It has underperformed by 15.45% the S&P500.

More notable recent Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) news were published by: Benzinga.com which released: “Jazz Pharma Investors: Did You Catch This Favorable Ruling?” on April 13, 2016, also Schaeffersresearch.com with their article: “Jazz Pharmaceuticals, Snap, Transocean Stocks Moving Today” published on March 20, 2017, Benzinga.com published: “Martin Shkreli Thinks Jazz Pharmaceuticals Could Be Worth $20 Billion, While …” on September 12, 2016. More interesting news about Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) were released by: Benzinga.com and their article: “Jazz Pharmaceuticals Misses Earnings, Cuts Guidance” published on August 09, 2016 as well as Benzinga.com‘s news article titled: “Jazz Pharma To Evaluate If Generic Xyrem’s FDA Waiver Meets Required Legal …” with publication date: January 18, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.